Compound Screening Development Drugs Trials 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges .
Drug Discovery World
JANUARY 26, 2023
DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. billion showed the pharma giant taking further steps into the oncology market and developing its speciality medicines vaccines portfolio.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 22, 2024
This article is sponsored by Collaborative Drug Discovery. Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Users can also export data into Excel, so outgoing files can be password protected.
Drug Discovery World
JANUARY 23, 2023
In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Clinical trials revealed eight out of nine predictions were correct. We witnessed the unprecedented pace of vaccine development, fuelled by cutting-edge mRNA technology. modulation of target X plays a role in the downstream biology of disease Y.
Drug Discovery World
AUGUST 15, 2023
Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods? Such techniques, if routinely deployed in drug discovery, may enable improved decision making in predicting serious adverse cardiovascular events.
Expert insights. Personalized for you.
52 
Let's personalize your content